|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.8 CHF | -0.16% |
|
+2.41% | -7.93% |
| Apr. 15 | ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating | ZD |
| Apr. 15 | Roche: positive phase III data in lymphoma | CF |
(Reuters) - Johnson & Johnson said on Monday John Reed will take the role of executive vice president of pharmaceuticals, research and development, effective April 3.
Reed, 64, will replace William Hait, who was appointed the interim head of the unit in August 2022.
Reed has previously served in executive positions for drugmakers Sanofi SA and Roche Holding AG.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 224.8 CHF | -0.16% | +2.41% | 199B | ||
| 86.76 EUR | -0.79% | -0.26% | 116B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -7.93% | 199B | |
| +28.79% | 676B | |
| +25.94% | 559B | |
| -5.84% | 356B | |
| +15.75% | 320B | |
| +4.32% | 286B | |
| +4.00% | 213B | |
| +1.92% | 207B | |
| -10.00% | 147B | |
| -7.82% | 142B |
ROCHE HOLDING AG 
